BioCryst Pharmaceuticals (NASDAQ:BCRX) Announces Quarterly Earnings Results, Beats Estimates By $0.05 EPS

BioCryst Pharmaceuticals (NASDAQ:BCRX) posted its quarterly earnings data on Wednesday. The biotechnology company reported $0.14 EPS for the quarter, beating the consensus estimate of $0.09 by $0.05, Zacks reports. BioCryst Pharmaceuticals had a negative return on equity of 86.89% and a negative net margin of 40.90%. The business had revenue of $180.29 million for the quarter, compared to the consensus estimate of $165.67 million. During the same quarter in the prior year, the business earned $0.06 earnings per share. BioCryst Pharmaceuticals’s revenue for the quarter was up 13.1% on a year-over-year basis.

Here are the key takeaways from BioCryst Pharmaceuticals’ conference call:

• ORLADEYO revenue was $174.8 million, up 20% year over year excluding Europe, but included an upper-teens-million-dollar, one-time contribution from CareMed’s inventory build. BioCryst kept its full-year ORLADEYO guidance at $625 million–$645 million, saying future revenue should more closely reflect patient demand.
• BioCryst reported non-GAAP operating profit of $86 million, up 70% year over year, and non-GAAP net income of $71 million, more than doubling. It raised total 2026 revenue guidance to $715 million–$730 million, tightened operating expense guidance to $415 million–$425 million, and expects restructuring actions to generate $30 million–$35 million in annualized savings.
• Management described ORLADEYO prescriptions and net patient additions as strong, with early pediatric demand ahead of expectations and potential to exceed the previously estimated 500-patient opportunity. The company also launched pediatric pellets and plans to offer a newly approved 150 mg pellet formulation for patients 12 and older.
• The navenibart pivotal trial is fully enrolled, with 12-month top-line data expected in the third quarter of 2027; BioCryst is also preparing its BLA and launch plans. The company expects early BCX17725 data in Netherton syndrome by year-end and is evaluating early-stage external opportunities, but said further investment and development decisions will depend on the data and scientific assessment.

BioCryst Pharmaceuticals Stock Performance

BioCryst Pharmaceuticals stock traded down $0.59 during midday trading on Thursday, hitting $7.65. 966,139 shares of the company’s stock were exchanged, compared to its average volume of 4,904,068. The company has a market cap of $1.95 billion, a P/E ratio of -5.15 and a beta of 0.55. The stock has a 50-day moving average price of $8.55 and a two-hundred day moving average price of $8.74. BioCryst Pharmaceuticals has a 52-week low of $6.23 and a 52-week high of $11.22.

BioCryst Pharmaceuticals News Summary

Here are the key news stories impacting BioCryst Pharmaceuticals this week:

• Positive Sentiment: Q3 adjusted earnings were $0.14 per share, above the $0.09 consensus and up from $0.06 a year earlier. Revenue rose 13.1% year over year to $180.29 million, beating estimates of $165.67 million; the company also reported higher net income and increased its 2026 revenue guidance. These results and the improved outlook may support investor confidence. BioCryst Q3 results and guidance
• Positive Sentiment: Management’s earnings-call discussion highlighted continued growth for ORLADEYO, BioCryst’s key commercial product, adding to the growth narrative. Earnings call highlights
• Neutral Sentiment: Wedbush lowered its BCRX price target to $17 from $18 but maintained an “outperform” rating. The target reduction is a cautionary note, while the retained rating remains bullish. Wedbush recommendations

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on BCRX shares. Wall Street Zen raised BioCryst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Saturday, October 24th. Royal Bank Of Canada lowered BioCryst Pharmaceuticals from an “outperform” rating to a “sector perform” rating and decreased their price objective for the stock from $13.00 to $11.00 in a report on Thursday, September 10th. Wedbush lowered their price objective on BioCryst Pharmaceuticals from $18.00 to $17.00 and set an “outperform” rating on the stock in a research note on Thursday. Needham & Company LLC reaffirmed a “buy” rating and set a $16.00 price objective on shares of BioCryst Pharmaceuticals in a report on Tuesday, September 8th. Finally, Weiss Ratings lowered shares of BioCryst Pharmaceuticals from a “hold (c)” rating to a “sell (d-)” rating in a research report on Tuesday, September 22nd. Six analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $20.38.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc is a biotechnology company focused on developing and commercializing oral medicines for rare and serious diseases. The company uses structure-based drug design and small-molecule research to develop therapies intended to address conditions with limited treatment options.

BioCryst’s primary commercial product is Orladeyo (berotralstat), an oral medication used to prevent hereditary angioedema attacks in adults and pediatric patients aged 12 and older. The company also maintains a pipeline of investigational therapies for complement-mediated diseases and other rare disorders, including programs designed to inhibit components of the complement system.

Founded in 1986 and headquartered in Durham, North Carolina, BioCryst has historically conducted research and commercial activities in the United States and worked with international partners to make its products available in additional markets.